Toyonaka, Japan
Toyonaka, Japan

Time filter

Source Type

Patent
Shionogi & Co. | Date: 2016-12-27

Disclosed is a compound which is useful as an AMPK activator. A compound represented by formula: or a pharmaceutically acceptable salt thereof, wherein R^(4 )is hydrogen, or substituted or unsubstituted alkyl,R^(1), R^(2 )and R^(3 )are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl or the like, with the proviso that R^(1), R^(2 )and R^(3 )are not simultaneously hydrogen,X is a single bond, S, O, NR^(5), C(O) or the like,R^(5 )is hydrogen, or substituted or unsubstituted alkyl,Y is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl or the like.


Patent
Shionogi & Co. and ViiV Healthcare | Date: 2017-02-08

The present invention is to provide a novel compound (I) shown below, having the anti-virus activity; particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein


Patent
Shionogi & Co. | Date: 2017-06-21

We provide a novel and useful process for preparing triphenyl-butene derivative. A process for the preparation of a compound represented by Formula (IV):^(1) is hydrogen or substituted or unsubstituted alkyl,characterized by reacting a compound represented by Formula (V):^(1) has the same meaning as defined above,in the presence of 1) a polyvalent metal chloride, 2) a reducing agent and 3) an alkali metal salt and / or a substituted or unsubstituted phenol.


Patent
University of Tokyo, Tohoku University and Shionogi & Co. | Date: 2017-02-24

A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: wherein R^(1), R^(2), R^(3), R^(4a), R^(4c), R^(5 )are as defined in the description.


Patent
Purdue Pharma and Shionogi & Co. | Date: 2017-03-10

The disclosure relates to Compounds of Formula (I) and pharmaceutically acceptable derivatives thereof, where R_(1), R_(4), R_(8), R_(9), and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, pain associated with osteoarthritis, osteoarthritis, UI, an ulcer, IBD, and IBS, comprising administering to an animal in need thereof an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof.


Patent
Purdue Pharma and Shionogi & Co. | Date: 2017-05-31

The disclosure relates to Compounds of Formula (I)_(1), R_(4), R_(8), R_(9), and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, pain associated with osteoarthritis, osteoarthritis, UI, an ulcer, IBD, and IBS, comprising administering to an animal in need thereof an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof.


The present invention provides a compound which has an effect of inhibiting amyloid production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or phylactic agent for diseases induced by production, secretion and/or deposition of amyloid proteins. A compound of the formula (I) wherein X is -S- or -O-, R3a is alkyl, haloalkyl or the like, R2a is H, halogen, alkyloxy, haloalkyloxy or the like, R2b is H or the like, R3b is H or alkyl, ring A and ring B is each independently a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle or the like, and R1 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof.


The present invention provides an acid addition salt or a sodium salt of a compound represented by the formula (IA):


Patent
National Cerebral And Cardiovascular Center, Osaka University and Shionogi & Co. | Date: 2017-07-12

The present invention relates to a natriuretic peptide receptor GC-B agonist for use in preventing or suppressing the metastasis of a malignant tumor, wherein the natriuretic peptide receptor GC-B agonist is any one selected from the following (b1) to (b5) or a pharmacologically acceptable salt thereof and has an agonist activity for the natriuretic peptide receptor GC-B: (b1) a c-type natriuretic peptide consisting of the amino acid sequence of SEQ ID NO: 7, 8, 9 or 10, (b2) a substance comprising an active fragment, where in it has the amino acid sequence of SEQ ID NO: 11, or wherein it consists of the amino acid sequence from position 6 to position 22 of SEQ ID NO: 7, (b3) a mutant wherein it is (i) a peptide consisting of the amino acid sequence of SEQ ID NO: 7, 9 or 10 having substitution, deletion, insertion, and/or addition of one to several amino acids selected from positions 1 to 5, (ii) a peptide consisting of the amino acid sequence of SEQ ID NO: 8 having substitution, deletion, insertion, and/or addition of one to several amino acids at any one to several positions selected from positions 1 to 36: (b4) a derivative comprising any one of the amino acid sequences of SEQ ID Nos: 7 to 11, wherein the derivative preferably further comprises at least one of the Fc region of an immunoglobulin, a serum albumin, and the C-terminus of ghrelin, and (b5) a modified form wherein it comprises any one of the amino acid sequences of SEQ ID Nos: 7 to 10 of the sequence listing, and at least one amino acid other than the amino acids shown in SEQ ID NO: 11 is chemically modified, or wherein it is prepared by chemical modification by addition of a pharmaceutically usable polymer.


The present invention relates to a stable pharmaceutical composition comprising a compound represented by formula (I), its pharmaceutically acceptable salt or a solvate thereof. The stable pharmaceutical composition can be prepared by comprising 1) a compound represented by formula (I), its pharmaceutically acceptable salt, or a solvate thereof, 2) one or more selected from the group consisting of alkali metal chlorides, alkaline earth metal chlorides, transition metal chlorides and magnesium chloride; and 3) sugar and/or a sugar alcohol.

Loading Shionogi & Co. collaborators
Loading Shionogi & Co. collaborators